Advertisement
MKGAY.PK Berita Valas
Merck KGaA Posts Weak FY23 Results; Sees Organic Growth In FY24
German science and technology major Merck KgaA reported Thursday weak profit and sales in fiscal 2023 amid a challenging market environment. Higher sales in Healthcare business sector were more than offset by weakness in Life Science and Electronics. Looking ahead for fiscal 2024, Merck expects return to organic growth with slight to moderate organic growth in sales and EBITDA pre, with Healthca
RTTNews
|
533 days ago
Merck KGaA Sees FY23 Results At Lower Half Of Outlook Range, Organic Sales Growth In FY24; Stock Up
German science and technology major Merck KgaA Thursday reconfirmed its earnings and sales forecast for fiscal 2023, but at the lower half of the range after reporting weak profit and sales in its third quarter amid a difficult market environment. Further, the company projects a return to organic sales growth in fiscal 2024. The shares were gaining around 5 percent in the morning trading in German
RTTNews
|
652 days ago
Merck KgaA Profit Rises, Ups Dividend; Sees Weak To Flat EBITDA Pre In FY23
German science and technology major Merck KgaA reported Thursday higher profit and revenues in its fiscal 2022, with improved performance in all divisions. The company further lifted its dividend, and said it expects weak to flat EBITDA pre in fiscal 2023, but higher organic sales.
RTTNews
|
904 days ago
Merck KGaA Aims To Launch One New Product Or Major Indication Every 1.5 Years On Average
While providing updates on the company's healthcare research and development strategy, aimed at doubling R&D productivity on Monday, German science and technology firm Merck KGaA (MKGAY.PK) said it will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an increased focus on external innovation.
RTTNews
|
1005 days ago
